Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer
- 1 August 2018
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 288 (2), 485-491
- https://doi.org/10.1148/radiol.2018170425
Abstract
Purpose To determine the association between Prostate Imaging Reporting and Data System (PI-RADS) version 2 scores and prostate cancer (PCa) in a cohort of patients undergoing biopsy of transition zone (TZ) lesions. Materials and Methods A total of 634 TZ lesions in 457 patients were identified from a prospectively maintained database of consecutive patients undergoing prostate magnetic resonance imaging. Prostate lesions were retrospectively categorized with the PI-RADS version 2 system by two readers in consensus who were blinded to histopathologic findings. The proportion of cancer detection for all PCa and for clinically important PCa (Gleason score ≥3+4) for each PI-RADS version 2 category was determined. The performance of PI-RADS version 2 in cancer detection was evaluated. Results For PI-RADS category 2 lesions, the overall proportion of cancers was 4% (one of 25), without any clinically important cancer. For PI-RADS category 3, 4, and 5 lesions, the overall proportion of cancers was 22.2% (78 of 352), 39.1% (43 of 110), and 87.8% (129 of 147), respectively, and the proportion of clinically important cancers was 11.1% (39 of 352), 29.1% (32 of 110), and 77.6% (114 of 147), respectively. Higher PI-RADS version 2 scores were associated with increasing likelihood of the presence of clinically important PCa (P < .001). Differences were found in the percentage of cancers in the PI-RADS category between PI-RADS 3 and those upgraded to PI-RADS 4 based on diffusion-weighted imaging for clinically important cancers (proportion for clinically important cancers for PI-RADS 3 and PI-RADS 3+1 were 11.1% [39 of 352] and 30.8% [28 of 91], respectively; P < .001). Conclusion Higher PI-RADS version 2 scores are associated with a higher proportion of clinically important cancers in the TZ. PI-RADS category 2 lesions rarely yield PCa, and their presence does not justify targeted biopsy. © RSNA, 2018 Online supplemental material is available for this article.Keywords
Funding Information
- NIH Clinical Center (BC011242-08)
- National Cancer Institute
This publication has 22 references indexed in Scilit:
- Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate CancerJournal of Urology, 2017
- Prostate Cancer Detection with Multiparametric Magnetic Resonance ImagingChinese Medical Journal, 2016
- Standardized Reporting of Prostate MRI: Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and Version 2PLOS ONE, 2016
- Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer DetectionJournal of Urology, 2016
- Prostate cancer detection with magnetic resonance‐ultrasound fusion biopsy: The role of systematic and targeted biopsiesCancer, 2016
- Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR ImagingRadiology, 2015
- Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate CancerJAMA, 2015
- The Expanding Role of MRI in Prostate CancerAmerican Journal of Roentgenology, 2013
- Utility of Multiparametric Magnetic Resonance Imaging Suspicion Levels for Detecting Prostate CancerJournal of Urology, 2013
- Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy Improves Cancer Detection Following Transrectal Ultrasound Biopsy and Correlates With Multiparametric Magnetic Resonance ImagingJournal of Urology, 2011